What does Inspire Medical do and what are its main business segments?

What is the revenue and EPS growth rate for Inspire Medical year over year?

What is Inspire Medical's latest dividend and current dividend yield?

What guidance did Inspire Medical's management provide for the next earnings period?

What were the key takeaways from Inspire Medical’s earnings call?

What factors drove the changes in Inspire Medical's revenue and profit?

Did Inspire Medical beat or miss consensus estimates last quarter?

What were the key takeaways from Inspire Medical's earnings call?

- **Reimbursement Risk Drives Guidance**: 2026 revenue range $950M-$1B reflects 10%-50% fee reduction uncertainty, with Q1 flat due to coding transition.
- **Inspire 5 Dominance**: 90%+ centers now using Inspire 5, driven by 79.5% responder rate and reduced surgical complexity.
- **Financial Resilience**: 2025 net income $420M, operating cash flow $117M; 2026 focus on 6%-8% adjusted margin despite top-line headwinds.
- **Strategic Mitigation**: Pursuing new CPT code, expanding field clinical reps, and enhancing digital tools to maintain patient flow.

**【Management Opening Remarks】**
- Ezgi Yagci provided forward-looking statements and risk disclosures, emphasizing the dynamic reimbursement landscape and the company's focus on patient outcomes.

**【CEO Summary Section】**
- **Reimbursement Clarification**: The Inspire 5 procedure will transition to CPT code 64582 with a -52 modifier, reducing the professional fee by 10%-50%. The company is working to minimize this reduction, citing the higher surgical complexity of Inspire 5.
- **Inspire 5 Performance**: Demonstrated superior outcomes (79.5% responder rate vs. 66% for Inspire 4) and reliability (0.5% device explants, 1.5% revisions). Over 90% of centers are now implanting Inspire 5.
- **2025 Results**: Q4 revenue $269M (+12% YoY), full year $912M (+14% YoY). Operating margin improved due to sales leverage and higher Inspire 5 mix.
- **Strategic Initiatives**: Focus on territory consolidation, field clinical rep expansion, and digital tools like SleepSync to enhance patient access.

**【CFO Financial Commentary】**
- **Q4 2025 Financials**: Net income $420M, Non-GAAP EPS $1.08 (exceeding expectations). Operating cash flow $52M, full year $117M. $175M share repurchases completed.
- **2026 Outlook**: Revenue guidance $950M-$1B (+4%-10%), reflecting reimbursement uncertainty. Adjusted operating margin 6%-8%, adjusted EPS $1.85-$2.35. Focus on cost discipline and tax rate management.

**【Q&A Key Highlights】**
- **Reimbursement Clarity Timeline**: Expect more data by mid-2026; 3 of 7 MACs have implemented the -52 modifier. Commercial payers may follow Medicare's lead.
- **Dual Strategy**: Pursuing a new CPT code (effective 2028) while advocating for smaller fee reductions. Inspire 4 inventory available for centers hesitant to transition.
- **WISeR Program Impact**: Q1 disruption in 6 pilot states, but prior authorization support is mitigating delays.
- **Competitive Landscape**: Confident in Inspire 5's clinical superiority; minimal impact from competitors' stocking strategies.
- **Cost Discipline**: 2026 capex $45M-$50M, with focus on R&D (e.g., MRI compatibility, Inspire 6 auto-activation feature).

Inspire Medical Systems, Inc. (INSP) Q4 2025 Earnings Call Transcript

- **Revenue Beat**: Q3 2025 revenue $224.5M (+10% YoY), full year guidance reaffirmed at $900-910M
- **Inspire V Adoption**: 75% U.S. centers now implanting V, surgical time down 20%, 6+ hours nightly use in 100+ patients
- **Clinical Validation**: Studies show Inspire V reduces cardiovascular morbidity vs. CPAP, with 87% inspiratory overlap success
- **Financial Strength**: Operating cash flow $68.5M, $125M share buybacks year-to-date, EPS guidance raised to $0.90-1.00
- **2026 Outlook**: CEO hints at 10-11% growth, citing inventory transition and GLP-1 competition, with Q4 2025 one-time tax benefit of $10-20M

**【CEO Summary Section】**
- **Revenue Growth**: Q3 2025 revenue of $224.5M, up 10% YoY, driven by Inspire V adoption. Full year guidance reaffirmed at $900-910M (12-13% growth). 
- **Inspire V Momentum**: 75% of U.S. centers now implanting V, with 20% reduction in surgical time vs. IV. Singapore clinical study showed 87% inspiratory overlap success.
- **Clinical Evidence**: Studies demonstrate Inspire V reduces cardiovascular morbidity vs. CPAP, with 6+ hours nightly use in 100+ U.S. patients.
- **Marketing Impact**: New ad campaigns (e.g., "Dream Again" featuring Chock Chappele) show early engagement, with 98% physician training completion.
- **Reimbursement**: CMS increases CPT 64568 reimbursement by 11% to $660, effective Jan 2026. ASC reimbursement up 5% to $28,000.

**【CFO Financial Commentary】**
- **Financial Highlights**: 
  - Q3 GAAP net income: $9.9M ($0.34 EPS) vs. $18.5M ($0.60 EPS) prior year
  - Adjusted EBITDA: $44M (20% margin) vs. $44.5M (22% margin) prior year
  - Operating cash flow: $68.5M (year-to-date $64.5M)
- **Expense Management**: 
  - Total OpEx $183.1M (+17% YoY) due to patient marketing
  - R&D down 17% YoY as focus shifts to V scale
  - Legal costs $1.3M (DOJ investigation, patent lawsuits)
- **Guidance Updates**: 
  - Full year EPS raised to $0.90-1.00 (prev $0.40-0.50)
  - 2025 tax rate 25% (higher state minimums)
  - $125M share buybacks year-to-date

**【Q&A Key Highlights】**
- **2026 Outlook**: CEO hints at 10-11% growth (vs. 2025's 12-13%), citing Inspire IV inventory transition and GLP-1 competition
- **Inventory Transition**: 98% U.S. centers on V, with IV manufacturing winding down. Global IV supply needed for Europe/Asia
- **Expense Trends**: CFO expects OpEx growth to moderate in 2026, with focus on DTC marketing efficiency
- **Competitive Dynamics**: New competitor in early stages, no material impact yet. Inspire V adoption rates >90% in trained centers
- **Tax Benefit**: Q4 2025 will see $10-20M one-time tax benefit from deferred tax asset reversal

Inspire Medical Systems, Inc. (INSP) Q3 2025 Earnings Call Transcript

- **Revenue Downgrade**: 2025 revenue guidance reduced to $900-910 million (-4% midpoint) due to Inspire V adoption delays and inventory destocking.
- **Key Challenges**: SleepSync IT approvals (50% centers implemented), Medicare billing delays, and patient wait times for Inspire V.
- **Financial Impact**: Diluted EPS revised to $0.40-0.50 (down from $2.20-2.30) due to lower revenue and $11.5 million one-time stock-based compensation charge.
- **2026 Outlook**: CEO expects growth acceleration with improved reimbursement (+4-5% for hospitals/ASCs, +11% for surgeons) and 20%+ surgical efficiency gains from Inspire V.

**【CEO Summary Section】**
- **Revenue Guidance Adjustment**: Full year 2025 revenue revised to $900-910 million (down from $940-955 million), reflecting 12-13% growth vs. 2024. Key headwinds include delayed Inspire V adoption, SleepSync implementation challenges, Medicare billing delays, and inventory destocking of Inspire IV.
- **Inspire V Challenges**: Over 50% of U.S. centers have implemented SleepSync, but IT approvals and patient delays slowed adoption. Medicare billing for CPT 64568 only became effective July 1, causing centers to continue using Inspire IV.
- **Strategic Actions**: Increased patient marketing, territory expansion, and surgeon training to accelerate Inspire V adoption. Q3 revenue expected to grow 1-3% sequentially.
- **Long-Term Outlook**: Confident in 2026 growth acceleration, driven by improved reimbursement rates (+4-5% for hospitals/ASCs, +11% for surgeons) and clinical evidence showing 20% reduction in surgical time and 86% inspiratory overlap.

**【CFO Financial Commentary】**
- **Q2 2025 Results**: Revenue $217.1 million (+11% YoY), U.S. revenue $207.2 million (+10% YoY). Gross margin 84% (down 80bps due to Inspire IV component charge). Operating expenses $185.7 million (+15% YoY) due to sales expansion and one-time legal fees.
- **Financial Guidance**: Full year 2025 diluted EPS revised to $0.40-0.50 (down from $2.20-2.30) due to reduced revenue and increased marketing spend. Adjusted EBITDA margin maintained at 20%.
- **Liquidity**: $411 million cash on hand, supporting growth initiatives.

**【Q&A Highlights】**
- **Headwinds Quantification**: Centers completing SleepSync and Medicare billing delays were primary drivers of revenue reduction. Over 50% of U.S. centers now have SleepSync, with full implementation expected by Q3.
- **2026 Growth Expectations**: CEO confident in exceeding 2025 growth rate, citing improved reimbursement, expanded marketing, and clinical evidence showing 20%+ implant volume increase in early adopters.
- **EPS Impact**: $0.57 one-time charge for stock-based compensation included in revised guidance. Excluding this, underlying EPS reduction reflects lower revenue and increased DTC spend.
- **Inventory Management**: Inspire IV destocking headwinds factored into 2H guidance, but timing variability makes quantification challenging.


Inspire Medical Systems, Inc. (INSP) Q2 2025 Earnings Call Transcript

- **Landmark Milestone**: 100,000+ patients treated, with significant growth potential in underserved market.
- **Inspire V Launch**: Full U.S. rollout begins in May, featuring closed-loop tech and simplified implant process. Surgeons report 30-40% reduction in OR time.
- **Q1 Strong Performance**: 23% revenue growth to $201M, first-ever quarterly profit ($0.1 EPS). Full year guidance raised to $940-955M rev, $2.2-2.3 EPS.
- **Q2 Transition**: Mid-single-digit growth expected, with H2 acceleration as Inspire V adoption ramps.
- **Reimbursement Assurance**: 80%+ coverage under CPT 64568, including Medicare and commercial payers.
- **Operational Focus**: Scaling digital tools (SleepSync), expanding training programs, and adding 100+ APPs to boost provider capacity.


**【CEO Opening Remarks】**
- **100,000 patients milestone**: Highlighted as a key achievement, with significant growth potential in the lightly penetrated target market.
- **Inspire V Full Launch**: Announced for May 2025, featuring closed-loop hypoglossal nerve stimulation and advanced sensing capabilities. The system eliminates the need for a pressure-sensing lead, reducing OR time and improving surgeon experience.
- **Q1 2025 Financials**: Revenue of $201.3M (+23% YoY), net income of $3M (vs. $10M loss in Q1 2024). Full year 2025 guidance: $940-955M revenue (+17-19% YoY), EPS guidance raised to $2.2-2.3.
- **Transition Quarter (Q2)**: Expected mid-high single-digit sequential growth due to Inspire IV inventory destocking and patientwarehousing. Stronger growth anticipated in H2 2025.
- **Reimbursement**: CPT code 64568 now covers ~80% of 300M+ lives, including Medicare and commercial payers.
- **Market Expansion**: Added 120 ENT residents, 110 sleep fellows, and 90 new ENTs to training programs. Digital scheduling adoption growing to streamline patient flow.

**【CFO Financial Review】**
- **Revenue Breakdown**: U.S. $193.6M (+24% YoY), international $7.7M (-6% YoY). Gross margin stable at 84.7%.
- **Operating Expenses**: $172.1M (+11% YoY) driven by sales expansion and G&A costs. R&D and marketing expenses reduced YoY.
- **Cash Position**: $414M, supporting inventory build for Inspire V and share buybacks ($75M in Q1).
- **2025 Guidance**: Gross margin 84-86%, tax rate ~10%, diluted shares ~31M. Full year EPS raised to $2.2-2.3 (prev: $2.1-2.2).

**【Q&A Key Themes】**
1. **Q2 Dynamics**: Mid-high single-digit growth expected, with patientwarehousing (~$10-15M impact). H2 recovery driven by Inspire V adoption.
2. **Inspire V Acceptance**: Surgeons praise reduced OR time and simplified implant process. Early data shows strong surgeon satisfaction and procedure efficiency.
3. **Reimbursement Concerns**: 64568 code adoption broad, with CMS and commercial payers aligned. Tracking surgeon feedback on professional fee changes.
4. **Capacity Constraints**: Focus on adding APPs, expanding high-volume centers, and leveraging SleepSync for longitudinal patient management.
5. **International Strategy**: Submitting Inspire V for EU/Asia approval while maintaining IV sales during review periods.
6. **Patient Marketing**: Resuming DTC campaigns in Q2 to drive awareness and appointment scheduling through digital tools.


Inspire Medical Systems (INSP)-5 May 25-2025 Q1 Earnings call transcript

- **Q3 Revenue Beats by 5%**: $12.3B (+12% YoY), driven by 25% cloud growth and 18% AI solutions
- **$1B AI Investment**: 2-year R&D commitment for enterprise generative models
- **Margin Expansion**: 22.3% operating margin (140bps YoY improvement)
- **Key Risks**: 10%+ revenue at risk in recession scenario
- **China Recovery**: Low-single digit growth expected post-regulatory stabilization

**【CEO Opening Remarks】**
- Highlighted Q3 revenue of $12.3B (+12% YoY), driven by 25% growth in cloud services and 18% in AI solutions.
- Announced $1B investment in generative AI R&D over next 2 years, targeting enterprise use cases.
- Noted improving gross margin trends (+120bps QoQ) due to cloud scale efficiencies.

**【CFO Financial Breakdown】**
- GAAP EPS: $1.85 (vs. $1.60 consensus)
- Free cash flow: $3.2B (up 15% YoY)
- Operating margin: 22.3% (up 140bps YoY) due to cost optimization
- Guidance: Q4 revenue $12.8-13.2B (10-14% YoY growth)

**【Q&A Highlights】**
- China market: Regulatory environment stabilizing, expecting low-single digit growth
- AI talent acquisition: Completed 10+ startups acquisitions, +2,000 engineers added
- Supply chain: 90%+ component availability, no material shortages
- Risks: Macroeconomic uncertainty (10%+ revenue impact if recession)


Actual								-0.67	-0.88	-0.39	-0.28	-0.6	-0.48	-0.38	-0.09	-0.61	-0.53	-0.6	0.1	-0.53	-0.41	-0.29	0.49	-0.34	0.32	0.6	1.15	0.1	0.45	0.38	4.66
Forecast								-0.5875	-1.1055	-0.7215	-0.4583	-0.6597	-0.6409	-0.6145	-0.4373	-0.796	-0.6088	-0.7556	-0.6067	-0.6603	-0.5695	-0.58	-0.0535	-0.6514	-0.1398	0.0615	0.7315	-0.248	0.2019	-0.1894	0.6766
Surprise	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	-14.04%	+20.40%	+45.95%	+38.90%	+9.05%	+25.11%	+38.16%	+79.42%	+23.37%	+12.94%	+20.59%	+116.48%	+19.73%	+28.01%	+50.00%	+1015.89%	+47.80%	+328.90%	+875.61%	+57.21%	+140.32%	+122.88%	+300.63%	+588.74%

INSP

INSP fundamentals

INSP Q4 2025 Earnings

Earnings Call

You can ask Aime

INSP

INSP fundamentals

INSP Q4 2025 Earnings

Earnings Call

INSP Earnings Call Summary for Q4/20255:00 PM on Feb 11, 2026

INSP Earnings Call Summary for Q3/20255:00 PM on Nov 3, 2025

INSP Earnings Call Summary for Q2/20255:00 PM on Aug 4, 2025

INSP Earnings Call Summary for Q1/20255:00 PM on May 5, 2025

INSP Earnings Call Summary for Q4/20245:00 PM on Feb 10, 2025

You can ask Aime